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The success of many population studies is determined by proper matching of cases to controls. Some of
the confounding and bias that afﬂict electronic health record (EHR)-based observational studies may be
reduced by creating effective methods for ﬁnding adequate controls. We implemented a method to match
case and control populations to compensate for sparse and unequal data collection practices common in
EHR data. We did this by matching the healthcare utilization of patients after observing that more com-
plete data was collected on high healthcare utilization patients vs. low healthcare utilization patients. In
our results, we show that many of the anomalous differences in population comparisons are mitigated
using this matching method compared to other traditional age and gender-based matching. As an exam-
ple, the comparison of the disease associations of ulcerative colitis and Crohn’s disease show differences
that are not present when the controls are chosen in a random or even a matched age/gender/race algo-
rithm. In conclusion, the use of healthcare utilization-based matching algorithms to ﬁnd adequate con-
trols greatly enhanced the accuracy of results in EHR studies. Full source code and documentation of
the control matching methods is available at https://community.i2b2.org/wiki/display/conmat/.
 2014 Elsevier Inc. All rights reserved.1. Introduction
In the United States, electronic health record (EHR) adoption
has increased dramatically in recent years. In 2012, 44% of hospi-
tals reported having an operational EHR, up from 8.8% in 2008
[1]. The growth of EHRs has created large longitudinal data sets
that enable a variety of population studies. EHRs have been shown
to provide important strengths over other data sources, including
large, diverse populations representing real-world patterns of dis-
ease and treatment with a wide variety of data types [2–4]. Inves-
tigators have leveraged these data sources for testing targeted
hypothesis of drug-adverse effect associations [5–7] and compar-
ing effectiveness of established therapies [8]. More recently,
researchers have also aimed to identify novel genetic associations
to EHR-derived phenotypes [9]. In these studies, institutionsestablish a biorepository of discarded blood samples which are
linked to EHR data. DNA is extracted from collected samples and
used to conduct genotype–phenotype association studies [3,10,11].
Many of these EHR-based observational studies employ a case-
control design where a case population of patients with a disease
are identiﬁed and a set of control patients are used for statistical
comparisons. The validity of theses designs are quite sensitive to
the methods used to select a comparison group. In an optimal sce-
nario, selected controls should represent the population of individ-
uals who would have been identiﬁed and included as cases had
they also developed the disease used to deﬁne the cases [13].
One limitation of the EHR-based data sources, however, is data
may be sparse and unequally collected across patient populations.
This effect is determined, in part by the health status of the patient,
since patients who are very ill and have been seen for longer peri-
ods of time have more information in the EHR than healthier peo-
ple. This effect introduces a serious ascertainment bias [12,13] that
may adversely impact the proper interpretation of EHR-based
studies. For example, a case patient with a history of chronic dis-
ease X is much more likely to have recorded comorbidities or other
potential study outcome than a control patient selected based on
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ters with the healthcare system due to lack of a recorded disease.
Thus the primary aim of a control matching algorithm relying
on EHR data should be to ﬁnd proper controls in the context of a
heterogeneous patient population and inconsistent data collection
that may confound results [14]. However, many case-control stud-
ies relying on EHR or insurance claims data only employ traditional
methods to match based on patient age and gender [5]. Further-
more, the authors have been unable to identify methods for match-
ing controls speciﬁcally targeted to EHR data in the published
literature.
In this work we aim to investigate varying control matching
approaches to improve the selection of controls in the EHR of a
large health system. Cases are matched to 4 control groups of vary-
ing complexity ranging from randomly selected matches to match-
ing based on a combination of demographic and healthcare
utilization features. We evaluate our control matching methods
by analyzing the comorbidity proﬁle of two diseases related to
inﬂammatory bowel disease (IBD): ulcerative colitis (UC) and Cro-
hn’s disease (CD) using a reference standard created by a subject
matter expert as well as by comparing distribution of comorbidi-
ties when comparing the cases against each control group. The
detailed methods and source code of the matching algorithms
evaluated in this work are made publicly available as open source
software implemented on the Informatics for Integrating Biology
and the Bedside (i2b2) platform.2. Materials and methods
2.1. Data source and population
The Partners HealthCare electronic health record (EHR) includes
sociodemographic data, billing codes, laboratory results, problem
lists, medications, vital signs, procedure reports and narrative
notes from Massachusetts General Hospital (MGH) and Brigham
andWomen’s Hospital (BWH), as well as from community and spe-
cialty hospitals that are part of the Partners HealthCare system in
Boston (Massachusetts, USA). All patients with at least one ICD-9
diagnosis code between January 1998 and April 2012 at MGH or
BWH were selected for inclusion in a data set (referred to as a data
‘mart’), yielding 2.8 million patients drawn from about 5 million
unique patients in the Partners system. The data mart consists of
all electronic records for the study patients and can be managed
with the i2b2 server software (i2b2 v1.6, Boston, MA, USA)
[15,16]. The Partners Institutional Review Board approved all
aspects of this study.Table 1
Matching variables and bins.
Variable Bins
A Age 10-year age bins
G Gender 2 categorical bins
R Race 5 categorical bins
N Number of facts 8 bins of uniform distribution
F First observation date 8 bins of uniform distribution
L Last observation date 8 bins of uniform distribution2.2. Case and control pool deﬁnition
EHR phenotyping algorithms for Crohn’s disease (CD) and ulcer-
ative colitis (UC) developed by Ananthakrishnan using the same
data source were utilized to evaluate the matching algorithms in
this study [17]. A sample of 1200 patients’ charts with a diagnoses
of CD (ICD-9 555.⁄) or UC (ICD-9 556.⁄) were reviewed by a clinical
expert to determine true disease status. Using the chart review
results as a training dataset, a classiﬁcation model for UC and CD
was developed using coded data as well as structured elements
derived from narrative notes through natural language processing
(NLP). The CD and UC algorithms predicted cases with a ﬁxed spec-
iﬁcity of 97%, yielding a sensitivity of 69% and a positive predictive
value of 98% for CD and a sensitivity of 79% and a positive predic-
tive value of 97% for UC. The trained models were applied to the
full population yielding 5506 patients with CD and 5522 patients
with UC.A set of 2,688,958 patients without a diagnosis of UC or CD in
their medical record were selected for inclusion into a control pool.
Each matching algorithm will randomly match case patients to
patients selected from the control pool using the speciﬁed match-
ing criteria.
2.3. Control matching algorithms
For each patient in the case and control pool sets we extracted 3
demographic variables: age (A), gender (G), and race (R). In addi-
tion, 3 variables of healthcare utilization in the study period were
calculated: number of facts (N), year of the ﬁrst encounter in the
healthcare system (F) and year of most recent encounter in the
healthcare system (L). The number of facts refers to number of dis-
tinct encounters with the medical system and is a measure of
health care utilization. For example, an ofﬁce visit, a medication
prescription, and a diagnosis code each contribute 1 fact. Gender
and race groups were treated as categorical variables and matched
exactly to control patients. Age was grouped into bins of decades of
life (e.g. 0–9, 10–19). Healthcare utilization variables N, F and L
were treated as continuous variables and divided into 8 quantile
bins of uniform distribution (Table 1).
Each case patient was then matched to one patient in the con-
trol pool (1:1) using 3 different paired matching algorithms: age,
race and gender (AGR), number of health ‘‘facts’’ and ﬁrst and most
recent observation (NFL); and all matching factors (AGRNFL). For
each matching process, patients selected from the control pool
were only matched to one case patient (1:1 matching) without
replacement into control pool. Each case-control matched pair
was then assigned a pair identiﬁer for the matching analysis.
Where there were insufﬁcient controls to match all factors, the
non-categorical matching factors were relaxed iteratively until an
appropriate control is found. Since the control sampling uses a
greedy algorithm – cases matched ﬁrst are more likely to ﬁnd an
exact matched control – the order in which the cases were
matched was also randomized.
For illustration, a hypothetical case patient that is 85 years old,
male, of Asian descent, with an observation period of 2001–2008
and 390 healthcare facts who is unable to ﬁnd a control with the
exact parameters would iteratively relax the matching parameters
as follows: the age bin is relaxed downward one decile bin in an
attempt to ﬁnd a control aged 70–79 with other exact matching
parameter bins. If none is found, the age bin is relaxed upward to
ﬁnd a control aged 90–99 with other exact parameter bins. Bins
are only adjusted by 1 in either direction. If still no control is found,
the number of facts bin is relaxed down one bin and then up one
bin in the same way. The parameters are relaxed in this way until
a control is found. If no control is found the case patient is dis-
carded from the analysis. While a user can conﬁgure the algorithm
to assign which parameters to relax, in which order and the num-
ber of bins to relax, for this paper we relax only the continuous
parameters in the order A, N, F, L. Maximum adjustment of 1 bin
is used.
A detailed diagram of the matching protocol is described in the
ﬂowchart included in Fig. 1. In addition, full source code and
Fig. 1. Matching algorithm ﬂow diagram.
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the i2b2 framework is available at https://community.i2b2.org/
wiki/display/conmat/. The documentation contains additional
details on methods utilized in this paper.
As an additional control, we randomly sampled patients from
the control pool without any matching on factors. In this group,
control patients were unmatched to the cases (random). As a sen-
sitivity analysis and for additional comparisons patients were also
matched by each factor alone.
2.4. Assessing IBD-related comorbidities
2.4.1. Comorbidity deﬁnitions
A disease grouping ﬁle developed as part of the PheWAS
research was downloaded in May 2013 [18]. PheWAS groupings
are manually curated disease categories that generally follow the
3-digit code groupings within the ICD9 code system itself but mod-
iﬁed to include semantically related groups. For example, all
hypertension codes (401–405) are grouped together as one Phe-
WAS grouping. For the purposes of this study, we pruned the Phe-
WAS groups to exclude comorbidities with a frequency of less than
5 patients in either the cases or the matched controls were
excluded from the analysis due to limited power to detect a true
association. A total of 806 PheWAS groups were selected for
inclusion in the analysis.
2.4.2. Comorbidity associations
The magnitude of the association between the IBD-related diag-
nosis and a given comorbidity is based on the relative risk (RR)
between the disease and comorbidity calculated by constructing
2  2 contingency tables for each PheWAS group. Statistical signif-
icance and 95% conﬁdence intervals were calculated using the
chi-squared test [19].2.4.3. Clinical expert reference
In order to evaluate each matching algorithms’ ability to discern
clinically meaningful comorbidity association, a board-certiﬁed
gastroenterologist (ANA) reviewed the full list of PheWAS disease
groupings to indicate whether there existed prior literature
demonstrating an association between the diagnosis and IBD in
general. Identiﬁed comorbidities may have included associations
due to IBD-related treatments to account for problems such as
infections that are not directly associated with IBD, but could be
associated with the immunosuppression medications taken for
IBD. The resulting list was used as a reference set to empirically
compare the results of our case-control analyses across the disease
spectrum.2.5. Comparison of the matching algorithms
Each control set was compared to UC or CD case sets based on
the matching parameters as well as selected common comorbid-
ities in the general population. In addition, the distributions of all
comorbidity relative risks (RR) were visualized and compared
across control sets. The distributions of comorbidities reaching
statistical signiﬁcance by Bonferroni-adjusted p-value for each
control set were also reported. The ability of each case-control
experiment to detect likely comorbidity associations was evalu-
ated by transforming the estimated RR and associated standard
error into a binary indicator depending on whether the 95%
conﬁdence interval for the RR excluded or included unity. The
transformed binary classiﬁer was compared to the expert-derived
reference and the sensitivity (SE), speciﬁcity (SP) and positive
predictive value (PPV) was computed on the basis of statistical
signiﬁcance at alpha = 0.05 and alpha = 0.000062 (equal to
Bonferroni correction for multiple comparisons across all 806
comorbidities).
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The matching algorithm effectively matched controls to case
patients using the matching factors described. Table 2 compares
the UC and CD case patients to the Random, AGR, NFL and AGRNFL
matched controls on the basis of the demographic and healthcare
utilization variables deﬁned for matching. Notably, the patients
not matched on NFL had far fewer encounters in the healthcare
system. Even without matching, the gender distributions across
the control sets generally matched the cases suggesting gender
may not need to be included as a matching factor for UC and CD.
Table 3 provides relative risk associations between UC and CD
and selected comorbidities. In general, controls not matched on
utilization factors had signiﬁcant positive associations across all
of the selected comorbidities whereas the AGRNFL and NFL
matched sets had many fewer signiﬁcant at alpha = 0.05. Figs. 2
and 3 plot the distributions of the signiﬁcant comorbidities using
the Random, AGR, NFL, and AGRNFL algorithms. The curves further
indicate that a far greater number of associations are detected
when controls are matched only on demographic (AGR) factors.
Overall, the curves show the surprising tendency that when using
only random or demographic based matching nearly all comorbid-
ities are positively associated with UC and CD. Using the utilization
corrected matches (NFL), the associations are far fewer and more
evenly distributed between positive and negative associations.
Indeed, there is a nominal decrease of negative associations when
matching by all combined parameter AGRNFL when compared to
matching on healthcare utilization parameters NFL without demo-
graphic parameters AGR.
The empirical assessment of comorbidity associations identiﬁed
using a binary transformed RR emphasized the overall contribu-
tions of N, F, and L on the performance of each classiﬁer (Table 4).
For CD, the AGRNFL matching algorithm performed well with a
speciﬁcity of 92.9% (95% CI: 90.1–95.0%), a sensitivity of 33.1%
(95% CI: 25.1–42.1%) and a PPV of 56.0 (95% CI: 44.8–67.2%). In
contrast, the AGR algorithm was far more sensitive at the expense
of accuracy with a speciﬁcity of 54.6% (95% CI: 47.8–59.4%), a sen-
sitivity of 78.8% (95% CI: 70.1–85.6%) and a PPV of 32.2 (95% CI
26.8–37.6%). Matched controls for UC performed similarly: the
AGRNFL matching algorithm yielded a speciﬁcity of 92.0% (95%
CI: 89.1–94.2%), a sensitivity of 29.9% (95% CI: 22.3–38.8%) and a
PPV of 50.0 (95% CI: 38.8–61.2%). The AGR algorithm was againTable 2a
Comparison of matching characteristics of CD and matched control patients.
Demographics CD cases
N = 5196
Random controls
N = 5196
AG
N =
Mean SD Mean SD Me
Age, years 47.6 18.7 46.3 22.5 47.
Pct Pct Pct
Female gender 53.7 54.9 53.
Race/ethnicitya
White 86.7 66.1 86.
African American 3.3 6.5 3.3
Hispanic 2.2 8.2 2.2
Asian 1 3.1 1
Other 6.8 16.1 6.8
Healthcare utilization Median Q1 Q3 Median Q1 Q3 Me
Number of facts 246.5 96 587 32 9 122 35
Observation start, year 2002 1998 2006 2004 2000 2008 200
Observation end, year 2011 2009 2012 2009 2004 2011 201
a Race and ethnicity are collected using a single ﬁeld in the electronic medical recordmore sensitive with a speciﬁcity of 38.1% (95% CI: 33.6–42.9%), a
sensitivity of 86.1% (95% CI: 78.1–91.6%) and a PPV of 26.8% (95%
CI: 22.2–31.3%). Additional results evaluating matching based each
factor alone is included in the supplemental materials (Tables S1–
S4).4. Discussion
This study presents the result of a systematic, empirical evalu-
ation of case-control matching algorithms using varying number of
demographic and healthcare utilization factors. Our efforts
assessed the validity of matching patients based on their overall
usage of the healthcare system (and consequentially the documen-
tation of their disease state) as evidenced by the ability to detect
likely disease comorbidities deﬁned by an expert-derived reference
standard. We have demonstrated that matching patients on the
number of diagnoses, procedures and medications has a signiﬁcant
effect on speciﬁcity and positive predictive value of detecting likely
disease associations. Matching by both demographic and utiliza-
tion factors improves the precision of association detection by
nearly 75% compared to an unmatched control patients or controls
matched by demographics alone.
As in most case-control studies, we want matched controls to
be comparable to the cases without themselves having the study
disease or risk factors known to be associated with the outcome.
We want them to be a representative sample of the population that
produced the cases to ensure that the distribution of exposure is
the same between the two groups. We want to take into account
criteria, such as age, gender and race that are often strong con-
founders of disease. Using the number of facts as a proxy for
healthcare utilization, as we do in this method, is another way to
promote comparability between the cases and controls. This is
especially important when using hospital-based populations for
selecting the cases and controls. When the hospital population is
heterogeneous, as can occur in tertiary referral hospitals, it is difﬁ-
cult to ensure that the patients have the same exposure to oppor-
tunities for recording their disease state, leading to selection bias
or confounding. Unfortunately, we do not have the consistent data
collection for each patient that is common in clinical trials. This
leads to an ascertainment bias that is inherent in every EHR-based
observational study. We partially account for the heterogeneity of
our population on this axis by matching on healthcare utilization.R matched controls
5196
NFL matched controls
N = 5196
AGRNFL matched controls
N = 5196
an SD Mean SD Mean SD
6 18.9 52.1 21.5 47.9 18.8
Pct Pct
7 58.3 53.7
7 72.1 86.7
6.4 3.3
9.1 2.2
3.1 1
9.3 6.8
dian Q1 Q3 Median Q1 Q3 Median Q1 Q3
10 129 213 79 475 206.5 77 462
4 2000 2008 2002 1998 2006 2002 1998 2006
0 2004 2011 2011 2009 2012 2011 2008 2012
, so subjects who identify as Hispanic are not further characterized.
Table 2b
Comparison of matching characteristics of UC and matched control patients.
Demographics UC cases Random controls AGR matched controls NFL matched controls AGRNFL matched controls
N = 5228 N = 5228 N = 5228 N = 5228 N = 5228
Mean SD Mean SD Mean SD Mean SD Mean SD
Age, years 51 18.4 46 22.5 50.8 18.5 51.7 21.3 51 18.5
Pct Pct Pct Pct Pct
Female gender 52.9 54.6 52.9 59.6 52.9
Race/ethnicitya
White 85.6 66.9 85.6 71.4 85.6
African American 2.7 6.5 2.7 7.5 2.7
Hispanic 2.6 8.1 2.6 8.9 2.6
Asian 1.7 3.2 1.7 3 1.7
Other 7.3 15.3 7.3 9.2 7.3
Healthcare utilization Median Q1 Q3 Median Q1 Q3 Median Q1 Q3 Median Q1 Q3 Median Q1 Q3
Number of facts 252 95 570.5 30 9 114 37 10 131 225 79 487 223 79 486
Observation start, year 2001 1998 2005 2004 2000 2008 2003 1999 2008 2001 1998 2005 2001 1998 2005
Observation end, year 2011 2009 2012 2009 2004 2011 2010 2004 2011 2011 2010 2012 2011 2010 2012
a Race and ethnicity are collected using a single ﬁeld in the electronic medical record, so subjects who identify as Hispanic are not further characterized.
Table 3a
Selected comorbidity associations with CD.
Comorbidity (lifetime history) CD vs. random CD vs. AGR CD vs. NFL CD vs. AGRNFL
RR RR RR RR
Asthma 1.30 + 1.28 + 0.88 0.90
Chronic airway obstruction 1.34 + 1.39 + 0.86 1.02
Chronic kidney disease 1.55 + 1.53 + 1.05 1.15 +
Congenital anomalies 1.29 + 1.35 + 0.97 0.95
Diabetes mellitus, Type 2 1.13 1.26 + 0.76  0.87
Disorders of lipoid metabolism 1.19 + 1.17 + 0.68  0.78 
Fractures 1.09 1.06 0.78  0.72 
Gastrointestinal hemorrhage 1.81 + 1.86 + 1.42 + 1.48 +
Headaches 1.27 + 1.21 + 0.82  0.80 
Heart failure 1.26 + 1.31 + 0.80  0.91
Hypertension 1.23 + 1.25 + 0.76  0.89 
Ischemic heart disease 1.17 + 1.24 + 0.76  0.90
Major depression 1.47 + 1.38 + 0.94 0.91
Malignant neoplasm 1.11 1.10 0.82  0.83 
Osteoarthrosis 1.28 + 1.19 + 0.78  0.87 
Rheumatoid arthritis 1.59 + 1.69 + 1.40 + 1.41 +
RR: relative risk.
+: signiﬁcant positive association (RR > 1).
: signiﬁcant negative association (RR < 1).
Table 3b
Selected comorbidity associations with UC.
Comorbidity (lifetime history) UC vs. random UC vs. AGR UC vs. NFL UC vs. AGRNFL
RR RR RR RR
Asthma 1.41 + 1.38 + 0.93 0.98
Chronic airway obstruction 1.35 + 1.19 0.86 0.91
Chronic kidney disease 1.60 + 1.51 + 1.04 1.15 +
Congenital anomalies 1.29 + 1.32 + 0.95 0.95
Diabetes mellitus, Type 2 1.32 + 1.27 + 0.84  0.91
Disorders of lipoid metabolism 1.49 + 1.40 + 0.89  0.91 
Fractures 1.18 + 1.15 + 0.83  0.80 
Gastrointestinal hemorrhage 2.14 + 2.09 + 1.75 + 1.80 +
Headaches 1.37 + 1.34 + 0.84  0.87 
Heart failure 1.36 + 1.27 + 0.86 0.90
Hypertension 1.41 + 1.30 + 0.86  0.92
Ischemic heart disease 1.33 + 1.25 + 0.86  0.87 
Major depression 1.44 + 1.40 + 0.97 0.91
Malignant neoplasm 1.23 + 1.16 + 0.91 0.93
Osteoarthrosis 1.44 + 1.35 + 0.96 0.93
Rheumatoid arthritis 1.72 + 1.67 + 1.36 + 1.40 +
RR: relative risk.
+: signiﬁcant positive association (RR > 1).
: signiﬁcant negative association (RR < 1).
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Fig. 2. Distribution of Crohn’s disease (CD) comorbidity associations with different
matched control patients. Each line represents a case-control comparison across
806 comorbidities using unmatched controls (CD97_Random), controls matched on
age, gender and race (CD97_AGR), controls matched on observation frequency and
period in the EHR (CD97_NFL) and controls matched on all factors (CD97_AGRNFL).
The y-axis represents the proportion of comorbidities meeting statistical signiﬁ-
cance (Bonferroni-adjusted) at the relative risk (RR). Lines are smoothed using a
Gaussian kernel function (Density).
Fig. 3. Distribution of ulcerative colitis (UC) comorbidity associations with different
matched control patients. Each line represents a case-control comparison across
806 comorbidities using unmatched controls (UC97_Random), controls matched on
age, gender and race (UC97_AGR), controls matched on observation frequency and
period in the EHR (UC97_NFL) and controls matched on all factors (UC97_AGRNFL).
The y-axis represents the proportion of comorbidities meeting statistical signiﬁ-
cance (Bonferroni-adjusted) at the relative risk (RR). Lines are smoothed using a
Gaussian kernel function (Density).
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of diagnoses, procedures and medications), which tend to
minimize errors that might occur if one particular variable were
unknowingly associated with the exposure.Table 4
Evaluation of matched controls using an expert-derived reference of IB
Cases Matched controls Sensitiv
Crohn’s disease (CD) Random 77.5 (6
AGR 78.8 (7
NFL 34.9 (2
AGRNFL 33.1 (2
Ulcerative colitis (UC) Random 84.7 (7
AGR 86.1 (7
NFL 30.2 (2
AGRNFL 29.9 (2Several limitations in our approach bear mentioning. First, the
case-control design as performed may have inherent limits for
detecting comorbidity associations. The matching process, though
it can be very effective in controlling for confounding variables,
requires effort to identify the correct confounders and to ensure
that the method is applied correctly to achieve meaningful results.
In addition, in contrast to a stratiﬁed analysis, a factor that has
been matched on cannot be examined in terms of how it affects
the outcome. Other potential problems could be that for some dis-
ease types there may be insufﬁcient controls to match to cases and
that matching on many variables may be statistically inefﬁcient if
we are not careful about which variables upon which to match.
Our approach for comparing the performance of matched con-
trols also has drawbacks. While the reference standard was derived
by clinical expert based on literature there may be some disagree-
ment among gastroenterologists about true associations. However,
as part of the goal of a PheWAS approach is to detect novel associ-
ations and patterns our aim was not to create a gold standard but
to compare the ability of each matching algorithm to identify clin-
ically meaningful associations that would be useful to a typical
investigator hoping to leverage this data to advance understanding
of a particular disease using EHR data from an active health
system.
In addition, the results may vary across different disease types.
For example, acute diseases or less well-deﬁned phenotypes may
perform differently. Nevertheless, we believe the methods
described will be effective in detecting novel associations that
can be validated with more traditional hypothesis-driven
investigation.
Finally, the philosophical question of what constitutes an opti-
mal control population is an ongoing one. Using hospital popula-
tions for matching may lead to selection of a number of sick
controls that may introduce unknown confounders. Indeed,
attempts to identify truly healthy controls with similar utilization
distributions have identiﬁed less than 2% of the population [20].
The number of diagnoses, medications, and procedures is a
crude indicator of both healthcare utilization and the completeness
of recording of the disease state of the patient. Clearly, patient
overall ‘‘sickness’’ is also being introduced as a comparator which
can lead to deleterious matching effects. The presence of negative
associations after NFL matching may be largely the result of this
effect. If a patient with a serious disease is matched to a patient
with an equally serious but different disease, the overall incident
of alternative serious diseases will increase. We speculate that
using more sophisticated measures of healthcare utilization, such
as the clinic type, provider specialty, insurance type (as a proxy
for socio economic status), and inpatient vs. outpatient status, will
improve our ability to match like patients without introducing this
effect.
In conclusion, the use of healthcare utilization factors to ﬁnd
adequate controls greatly enhanced the accuracy and utility of dis-
ease associated states found in the medical record. In this work, we
present an implementation of a case-control matching algorithmD comorbidity associations.
ity (%) Speciﬁcity (%) PPV (%)
8.8–84.4) 54.3 (49.5–59.1) 32.2 (26.8–37.6)
0.1–85.6) 54.6 (47.8–59.4) 32.2 (26.8–37.6)
6.8–43.8) 92.5 (89.6–94.6) 53.3 (45.4–67.1)
5.1–42.1) 92.9 (90.1–95.0) 56.0 (44.8–67.2)
6.7–90.5) 41.4 (36.7–46.2) 28.5 (23.8–33.2)
8.1–91.6) 38.1 (33.6–42.9) 26.8 (22.2–31.3)
2.5–39.1) 91.8 (88.9–94.1) 49.4 (38.2–60.5)
2.3–38.8) 92.0 (89.1–94.2) 50.0 (38.8–61.2)
V.M. Castro et al. / Journal of Biomedical Informatics 52 (2014) 105–111 111using variables that can be easily derived in most EHR data sources
and demonstrate the positive effect of ﬁnding controls with similar
frequencies of the number of recorded diagnoses, medications, and
procedures and their temporal distributions. Our work can be gen-
eralizable to a broad range of analyses using EHR data sources to
detect novel disease associations. These matching methods devel-
oped may also be leveraged to detect drug–disease associations or
identify and validate drug adverse effects.
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